Coeptis Therapeutics Holdings, Inc. announced a private placement of 4,300 Series A convertible preferred shares at a purchase price of $1,000 per share for gross proceeds of $4,300,000 led by new investor CJC Investment Trust on June 14, 2024. The Series A preferred share is convertible into shares at a price of $0.40 per share, subject to limitations. The company received funding pursuant to exemption provided under Regulation D. The transaction included participation from 7 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.289 USD | +1.05% | -6.77% | -63.13% |
06-17 | Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy | MT |
06-14 | Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.13% | 10.73M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding